ライフサイエンスコーパス: fludrocortisone

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ed salt and water intake in conjunction with fludrocortisone.

2 n a double-blinded fashion to receive either fludrocortisone 0.1 mg/day and salt 1 g/day or placebo t

3 corticoid excess, MF1 mice were treated with fludrocortisone (16 weeks) but did not reproduce the fun

4 ure to a commonly prescribed corticosteroid, fludrocortisone acetate (FLU), at concentrations between

5 Subjects were randomly assigned to receive fludrocortisone acetate, titrated to 0.1 mg/d (n = 50) o

6 e (24 mug/kg/h for 96 h), hydrocortisone and fludrocortisone alone, their respective combinations, or

7 If symptoms are troublesome, Fludrocortisone and B-blockers remain the favored drugs.

8 ogical therapies are available and generally fludrocortisone and midodrine are the drugs of first cho

9 Symptoms recurred in 10 of 18 children on fludrocortisone and salt and in 5 of 14 children on plac

10 were similar in the 18 children treated with fludrocortisone and salt compared with the 14 children o

11 Intravascular volume expansion with fludrocortisone and salt has been reported to be effecti

12 In our study of adults with CFS, fludrocortisone as monotherapy for NMH was no more effic

13 ure to identify symptomatic improvement with fludrocortisone does not disprove the hypothesis that NM

14 ith agents that increase central volume (eg, fludrocortisone, electrolyte-containing beverages), appe

15 reat analysis, 7 subjects (14%) treated with fludrocortisone experienced at least a 15-point improvem

16 (A randomised clinical trial of fludrocortisone for the prevention of vasovagal syncope;

17 y nonsignificant reduction in syncope in the fludrocortisone group (hazard ratio [HR]: 0.69: 95% conf

18 tion, there was a significant benefit due to fludrocortisone (HR: 0.51; 95% CI: 0.28 to 0.89; p = 0.0

19 ble-blind trial that assessed the effects of fludrocortisone in vasovagal syncope over a 1-year treat

20 th an orally administered mineralocorticoid, fludrocortisone, increased TSC expression (656 +/- 114%

21 studied the effects of the mineralocorticoid fludrocortisone on the abundance of NCC and its phosphor

22 severity of orthostatic hypotension, use of fludrocortisone or compression garments, or diagnosis.

23 Patients received either fludrocortisone or matching placebo at highest tolerated

24 l spells over a median of 9 years equally to fludrocortisone or placebo.

25 There is limited evidence whether being on fludrocortisone prevents vasovagal syncope.

26 its primary objective of demonstrating that fludrocortisone reduced the likelihood of vasovagal sync

27 s sought to determine whether treatment with fludrocortisone reduces the proportion of patients with

28 In a multivariable model, fludrocortisone significantly reduced the likelihood of

29 aily urine samples in 25 patients undergoing fludrocortisone suppression testing (100 mug every 6 hou

30 ht to evaluate the effectiveness of salt and fludrocortisone versus placebo in the prevention of sync

31 r, treatment with the salt-retaining steroid fludrocortisone, which is usually beneficial in primary

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。